Xcerra (XCRA) Tops Q2 EPS by 11c

Xcerra (NASDAQ: XCRA) reported Q2 EPS of $0.04, $0.11 better than the analyst estimate of ($0.07). Revenue for the quarter came in at $92.3 million versus the consensus estimate of $92.8 million.

Xcerra sees Q3 2015 EPS of $0.04-$0.09, versus the consensus of $0.07. Xcerra sees Q3 2015 revenue of $103-108 million, versus the consensus of $186.2 million.

For earnings history and earnings-related data on Xcerra (XCRA) click here.

You May Also Be Interested In

• BrainsWay Ltd. (BWAY) Reports In-Line Q3 EPS, Beats on Revenue; Offers FY26 Revenue Guidance
• Milestone Pharmaceuticals Inc. (MIST) Misses Q2 EPS by 2c
• Hemab Therapeutics Holdings (COAG) PT Raised to $60 at H.C. Wainwright